How effective is Tecfidera for Multiple Sclerosis? (a real world drug study)
Summary:
Overall ratings: 3.4/5 Long term ratings: 3.8/5
This is a phase IV clinical study of how effective Tecfidera (dimethyl fumarate) is for Multiple sclerosis and for what kind of people. The study is created by eHealthMe from 92 Tecfidera users and is updated continuously.
What is Tecfidera?
Tecfidera has active ingredients of dimethyl fumarate. It is often used in multiple sclerosis. eHealthMe is studying from 129,627 Tecfidera users. Check the latest studies of Tecfidera.
What is Multiple sclerosis?
Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,110 drugs and 1,354 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.
92 people are studied for taking Tecfidera in Multiple sclerosis
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Tecfidera effectiveness for Multiple sclerosis (number of people):
Overall:
- not at all: 6
- somewhat: 15
- moderate: 19
- high: 39
- very high: 13
Long Term:
- not at all: 1
- somewhat: 3
- moderate: 12
- high: 31
- very high: 11
Gender of people who take Tecfidera for Multiple sclerosis *:
- female: 80.43 %
- male: 19.57 %
Age of people who take Tecfidera for Multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 5.43 %
- 30-39: 23.91 %
- 40-49: 32.61 %
- 50-59: 23.91 %
- 60+: 14.13 %
Who find Tecfidera more effective for Multiple Sclerosis?
Gender of people who take Tecfidera for Multiple sclerosis *:
- female: 75 %
- male: 25 %
Age of people who take Tecfidera for Multiple sclerosis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 9.62 %
- 30-39: 17.31 %
- 40-49: 28.85 %
- 50-59: 32.69 %
- 60+: 11.54 %
* Approximation only. Some reports may have incomplete information.
Do you take Tecfidera?
- You can start a phase IV clinical trial to monitor Tecfidera safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Related studies
Alternative drugs to, pros and cons of:
- Tecfidera (129,627 reports)
Treatments, associated drugs and conditions:
- Multiple sclerosis (799,632 reports)
How the study uses the data?
The study is based on dimethyl fumarate (the active ingredients of Tecfidera) and Tecfidera (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Bi-Polar and Lacrimation Increased - 2 seconds ago
- Lacosamide and Status Epilepticus for Women aged 30-39 - 4 seconds ago
- Cialis and Colchicine drug interactions for men aged 40-49 - 7 seconds ago
- Provera vs. Loseasonique, side effect and effectiveness comparison - 9 seconds ago
- Paroxetine Hydrochloride and Anxiolytic Therapy for Women aged 60+ - 10 seconds ago
- Paroxetine Hydrochloride and Anxiety And Stress for Women aged 60+ - 10 seconds ago
- Paroxetine Hydrochloride and Tension for Women aged 60+ - 10 seconds ago
- Paroxetine Hydrochloride and Stress for Women aged 60+ - 11 seconds ago
- Paroxetine Hydrochloride and Anxiety, Apprehension, Feeling Uptight, Jitters, Stress, Stress And Anxiety, Tension for Women aged 60+ - 11 seconds ago
- Paroxetine Hydrochloride and Jitters for Women aged 60+ - 11 seconds ago